Research Article

Effects of Ligustilide on Tumor Growth and Immune Function in Institute of Cancer Research Mice

Rui Long¹,², Fang Yang², Jun-rong Du²*, Zhong-ming Qian², Chen-yuan Wang² and Chu Chen²

¹Department of Pharmacy, the First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, ²Department of Pharmacology and Biopharmaceutics, Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, West China School of Pharmacy, Sichuan University, Chengdu 610041, China

Abstract

Purpose: To investigate the immunomodulatory and antitumor activities of ligustilide (LIG) extracted from Angelica sinensis in mice.

Methods: Normal and tumor-bearing Institute of Cancer Research (ICR) mice were treated p.o. with LIG (5, 20 and 80 mg/kg/day) for 7 days. In normal ICR mice, phagocytosis of peritoneal macrophages and serum hemolysin concentration were assessed by chicken red blood cell ingestion test and quantitative hemolysis of sheep red blood cells assay, respectively. Lymphocyte proliferation was determined by 3-(4,5)-dimethylthiazdiazo (-z-y1)-3,5-di-phenytetrazoliumromide (MTT) method. Both cytotoxic T lymphocyte (CTL) and natural killer (NK) cell activities were evaluated by lactate-dehydrogenase-release assay. H22 ascites tumor cells were inoculated subcutaneously into ICR mice, followed by the determination of antitumor activity of LIG in the H22-bearing mice.

Results: LIG significantly increased thymus and spleen index, macrophage phagocytosis, serum hemolysin concentration, spleen lymphocyte proliferation and CTL and NK cell activities in normal ICR mice, but inhibited the growth of transplantable H22 hepatoma. The effect was dose-related but not in a linear fashion. A dose of 20 mg/kg dose was more effective than 5 and 80 mg/kg doses.

Conclusion: These results suggest that LIG at 20 mg/kg has a highly boosted the immune system and tumor inhibition.

Keywords: Angelica sinensis; Ligustilide; Immunomodulation; Antitumor; H22 hepatoma cells; ICR mice

Received: 18 July 2011 Revised accepted: 20 March 2012

*Corresponding author: Email: lrzj820@yahoo.com.cn
INTRODUCTION

Cancer is a major enemy threatening man's being. Common approaches for treating cancer include surgery [1], chemotherapy [2], radiotherapy [3] and gene therapy [4]. These modes usually come with side-effects. Hence, to find good cures and medicines has become increasingly become a major challenge to scientists. Immunomodulating agents can enhance or potentiate the host immune response against tumor without direct cytotoxicity to cancer cells [5].

In China, herbal remedies (i.e., specified mixtures of dried plant materials) have been utilized empirically. Chinese traditional medicines, as alternative cancer therapies, have recently attracted a great deal of attention due to their low toxicity [6,7]. *Radix Angelicae Sinensis,* (RAS) commonly known as “dong quai”, is highly regarded in Chinese traditional medicine [8]. The major components of plant are classified into essential oil and water-soluble substances [9]. The former is believed to be its main pharmacological active components [10]. However, the essential oil consists of at least sixty-seven constituents, most of which are a great variety of lactones [9]. It has been reported that the total *Angelica sinensis* lactones (ASL) could significantly enhance mouse cellular immune function in vitro [11]. However, due to the complexity of the total ASL, it is unclear which components in ASL play a vital role in affecting the host immune function. In addition, the mechanisms of immunomodulatory action of ASL are not fully understood.

Ligustilide (LIG), as the main component of ASL [12], has been shown to be effective in many pathological conditions such as cerebral ischemic damage [13], primary dysmenorrhea [14] and Alzheimer's disease [15]. However, the immunomodulatory and antitumor effects of LIG have not been reported yet. In the present work, the immunomodulatory effects of LIG, including non-specific, humoral and cellular immunity, were investigated in normal ICR mice. The antitumor activity of LIG was also studied in H22-bearing ICR mice.

EXPERIMENTAL

Preparation of LIG

*Radix Angelicae Sinensis* was purchased from the Danggui Cultivating Base of Good Agricultural Practice in Min Xian County, Gansu Province, China. The plant sample was collected in October, 2006, and the voucher specimen (no. 20061023) was deposited at the herbarium of West China School of Pharmacy, Sichuan University, Chengdu, China. Its identity was confirmed by Dr. Wang Chenyuan (West China School of Pharmacy, Sichuan University, Chengdu, China). LIG was prepared by a well-established procedure in our laboratory. Briefly, the essential oil of *Angelica sinensis* was extracted using a supercritical-CO₂ fluid system (the granule size of plant material, 60 μ; extraction temperature, 50 °C; extraction pressure, 10 MPa; extraction time, 2 h). LIG was isolated from the oil by silica-gel column chromatography and identified by electron impact ionisation MS, ¹H NMR and ¹³C NMR spectrometric techniques. The column was eluted with petroleum ether (bp, 60-90°C) and subsequently with petroleum ether-ethyl acetate (100:5). For chromatographic analyses, HPLC grade reagents and Alltima C18 column (5μm, 150mm×4.6 mm) were used. LIG peak was detected at an UV absorbance wavelength of 280 nm.

Experimental animals

Male ICR mice, weighing 20.0±2.0 g, were provided by the experimental animal institution (Academy of Medical Sciences, Sichuan, China), and housed under normal laboratory condition ( 22 ± 2 °C, 12/12-h light-dark cycle) with free access to standard rodent chow and water. The experimental protocol was approved by the Institutional Animal Ethics Committee of Sichuan University, Chengdu, China (approval ref no.
SCXK (Chuan) 2006-15), and followed the guidelines published by the National Institutes of Health [16].

Effect of LIG on immune function in normal ICR mice

The animals were randomly divided into four groups (n = 10): normal control group and 5, 20, 80 mg/kg LIG-treated groups. LIG was diluted in 3 % Tween-80 and administered p.o. for 7 days once daily. The normal control group was administered volume-matched vehicle (0.1 ml/10 g). On day 8, all the animals were sacrificed by decapitation. The mice, thymus and spleen were weighed, and the thymus and spleen indices were expressed as the thymus and spleen weight relative to mouse body weight.

Macrophage phagocytosis assay

Phagocytosis in the mice was performed using the methods of Lin et al [17] with some modifications. The mice were injected i.p. with 1.0 ml 2 % soluble starch 3 days prior to sacrifice. On day 8, the mice were injected i.p. with 0.5 ml 5 % cock red blood cells (CRBC). Thirty minutes later, the mice were sacrificed by decapitation. The peritoneal macrophages were washed by Hank's solution. After rubbing the abdomen, fluid from the abdominal cavity was collected to make two smears for each mouse. The smears were incubated at 37°C for 30 min in a wet box, washed by physiological saline solution, and then stained by Wright-Giemsa staining after quick drying. The number of CRBC ingested by 100 macrophages was counted in an optical microscope and expressed as phagocytosis index (PI), as in Eq 1, while phagocytic efficiency index (PEI) was determined as in Eq 2.

$$PI = \frac{N}{M} \quad (1)$$

where N is the number of total ingested CRBC and M is the number of macrophage ingesting CRBC

$$PEI (%) = \frac{M}{M_t} \times 100 \quad (2)$$

where M is the number of macrophage ingesting CRBC and M_t is the number of total macrophages.

Hemolysis of sheep red blood cells (QHS) assay

QHS assay was detected using the method described by Xu and Li [18]. In brief, 0.2 ml of 20 % sheep red blood cells (SRBC) prepared in normal saline was injected into the animals, i.p., 4 days prior to the assay. On day 4 following immunization, the mice were bledd and serum samples were diluted with normal saline to 1:500. A total of 1.0 ml 5 % SRBC and 1.0 ml 10 % guinea pig serum were mixed with 1.0 ml diluted serum and incubated for 30 min. After centrifugation at 2000 rpm for 10 min, the absorbance of the supernatant fluid was measured using a spectrophotometer (GBC Cintra 10e UV-visible spectrometer) at 540 nm. The blank/control (in duplicate) consisted of 1.0 ml 5 % SRBC, 1.0 ml 10 % guinea pig serum and 1.0 ml saline solution.

Mitogen-induced splenocyte proliferation

After sacrificing them, the mice were sterilized in 75 % ethanol. The spleens were extirpated on a clean bench. Under germ-free condition, single spleen cell suspension was prepared in cold phosphate buffered saline (PBS) by forcing spleen fragments through a fine nylon mesh. After washing twice in PBS, the cells were then resuspended to a concentration of $1 \times 10^6$ cells/ml in RPMI 1640 completely cultivated liquid (HyClone, USA), using low speed centrifugation (1000 rpm for 5 min).

Single spleen cell suspension (100 μl) was placed in each well of a 96-well microplate and 100 μl concanavalin A (ConA, 10 mg/l) or lipopolysaccharides (LPS, 100 mg/l) was added to each test well; RPMI1640 (100 μl) cultivated liquid was added to the control well. Following treatment in 5 % CO2-air mixture at 37 °C for 44 h, MTT (5 g/l, 10 μl) was added to each well and the plate
incubated for another 4 h. The supernatants were discarded. A total of 150 μl dimethyl sulfoxide was added to each well. The plate was then shaken until the crystals were dissolved. The absorbance, A$_{570}$, was detected on a microplate reader (Bio-Rad, Model 550, USA)

Assay of cytotoxic T lymphocyte (CTL)

The assay for cytotoxic T lymphocyte (CTL) activity was performed as described previously [7,19] with some modification. The splenocytes from each mouse were sensitized in vitro with mitomycin C-treated P815 mastocytoma cells at a responder/sensitizer ratio of 50:1 in a 5% CO$_2$–air mixture at 37 °C for 5 days. For the preparation of mitomycin C-treated P815 cells, cells (1×10$^5$ cells/ml) were incubated in the dark with mitomycin C at a concentration of 0.25 μg/ml for 30 min at 37 °C, and then the cells were washed four times. Following the sensitization phase, cultured spleen cells were harvested and resuspended in RPMI 1640 complete cultivated liquid, counted and diluted to 1×10$^6$ cells/ml for the determination of CTL activity. P815 cells (1×10$^5$ cells/ml) were co-cultured in duplicate with 100 μl splenic effector cells in a 96-well microplate (cell ratio of effector: target, 10:1). After incubating for 4 h at 37 °C, the plate was centrifuged at 1000 rpm/min for 5 min and the supernatant for each well (50 µl) was transferred into another 96-well microplate; 100 µl of lactic acid dehydrogenase substrate mixture was added to each well. After 3 min, 50 µl of 1M HCl was added to each well to stop the reaction. Finally, a microtiter plate reader (Bio-Rad, Modal 550, USA) was used for the evaluation of changes in the absorbance at a wavelength of 490 nm. To determine the percentage of killed target cells, Eq 3 was applied.

$$\text{CTL cell activity} (%) = \frac{(E-S)-(M-S)}{M-S} \times 100$$ …… (3)

where E is the experimental release of LDH activity from target cells incubated in the presence of lymphocytes, M the maximum release of LDH activity determined by lysing the target cells with 1% of NP-40, and S the spontaneous release of LDH activity from target cells incubated in the absence of lymphocytes.

Assay of NK cells activity

Single spleen cells suspension (1×10$^6$ cells/ml, 100 μl) and target cells YAC-1 (1×10$^5$ cells/ml, 100 μl) were placed in a 96-well microplate (effect: target ratio, 10:1). The cells were incubated in a 5% CO$_2$–air mixture at 37 °C for 4 h. Lactate dehydrogenase (LDH) activity was measured as described above.

Evaluation of antitumor activity

H$_22$ hepatoma cells were maintained in the peritoneal cavities of ICR mice provided by the experimental animal institution (Academy of Medical Sciences, Sichuan, China).

H$_22$ ascites tumor cells (about 5×10$^6$/ml) were inoculated subcutaneously (s.c.) into ICR male mice. Tumor size was measured using a caliper across its longest diameter (a) and the second longest diameter (b), and its volume was calculated using Eq 4.

$$V = 0.5ab^2.$$ ……………………………….. (4)

Treatment of the tumors was started after 7 days when the mice showed palpable tumors (minimal volume of 14 mm$^3$). The inoculated mice were randomized into five groups: 5, 20, 80 mg/kg LIG treatment groups, H$_22$-bearing mice as negative control group and cisplatin-treated mice as positive control group. Cis-diaminodichloroplatin (DPP, 2 mg/kg) was given to positive control group every week. LIG was diluted in 3% Tween-80 and administered p.o. once daily. In all cases, the tumors were measured every 3 days. Inhibition ratio (IR) was calculated using Eq 5.

$$\text{IR} (%) = \frac{(A - B)}{A} \times 100,$$ …………….. (5)
where A and B are the mean tumor volume of the negative control and treatment groups, respectively. All the mice were sacrificed after 15 days of treatment, when the longest diameter of tumors of control group exceeded 20 mm.

**Statistical analysis**

The results were expressed as mean ± standard deviation (SD). Statistical analysis was performed with SPSS 13.0. Analysis of variance was followed by Fisher’s least significant difference test. Differences were considered to be significant when p < 0.05.

**RESULTS**

**Effect of LIG on nonspecific immune function in normal ICR mice**

The purity of LIG was > 98 % based on the total peak area obtained by HPLC analysis in this study. As shown in Table 1, treatment with LIG (20 mg/kg) produced the highest number of thymus, and also yielded the greatest spleen index, phagocytosis index (PI) and phagocytic efficiency index (PEI); 5 and 20 mg/kg doses caused a significant increase in the above parameters (p < 0.05 and p < 0.001, respectively). Treatment with LIG (80 mg/kg) only slightly increased thymus, spleen index and macrophage phagocytosis, but no significant increase was observed in this group.

**Effect of LIG on humoral immune function in normal ICR mice**

Table 1 shows that treatment with LIG (20 mg/kg) significantly increased hemolysin concentration in normal ICR mice (p < 0.05). LIG (5 or 80 mg/kg) also increased antibody concentration in mouse serum, but the difference (compared with control) was not significant (p>0.05).

**Effect of LIG on cellular immunity in normal ICR mice**

The effect of LIG on induced proliferation of splenic lymphocytes (induced by Con A or LPS) is shown in Table 2, Con A-induced T lymphocyte proliferation was significantly increased at all LIG dose levels of 5, 20, 80 mg/kg (p < 0.001, p < 0.001, and p < 0.001, respectively), and the proliferation rate was 19.2, 27.6 and 10.3 %, respectively. LPS-induced B lymphocyte proliferation was also significantly increased (p < 0.001) at all LIG dose levels at the proliferation rate 16.2, 21.9 and 14.1%, respectively.

Enhancement of proliferation of splenic lymphocytes by LIG suggests that this compound may also affect the generation of cell-mediated cytotoxic responses. To test this, we examined the effect of LIG on the production of antigen-specific cytotoxic T lymphocytes (CTLs). The cytolytic activity of effector cells against p815 target cells was determined by lactate dehydrogenase activity assay. CTL activity increased at all three LIG doses in normal ICR mice (p < 0.001), as shown in Figure 1A.

**Table 1**: Effect of LIG on thymus and spleen indice, macrophage phagocytosis and serum hemolysin concentration in normal ICR mice (mean ± S.D, n=10)

<table>
<thead>
<tr>
<th>Group (mg/kg/d)</th>
<th>Thymus index (mg/g)</th>
<th>Spleen index (mg/g)</th>
<th>PEI (%)</th>
<th>PI</th>
<th>QHS A₅₆₀</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>1.89±0.51</td>
<td>6.09±0.62</td>
<td>37.39±3.60</td>
<td>1.01±0.06</td>
<td>0.403±0.075</td>
</tr>
<tr>
<td>5</td>
<td>2.57±0.84*</td>
<td>7.12±0.87*</td>
<td>45.33±3.97**</td>
<td>1.07±0.09*</td>
<td>0.481±0.069</td>
</tr>
<tr>
<td>20</td>
<td>3.02±0.90**</td>
<td>7.78±0.76**</td>
<td>48.06±3.44**</td>
<td>1.13±0.09**</td>
<td>0.510±0.057*</td>
</tr>
<tr>
<td>80</td>
<td>2.29±0.88</td>
<td>6.70±1.58</td>
<td>38.72±3.00</td>
<td>1.04±0.07</td>
<td>0.462±0.071</td>
</tr>
</tbody>
</table>

* p< 0.05, ** p< 0.001, compared with control group.
Table 2: Effects of LIG on spleen lymphocyte proliferation, CTL and NK activity in normal ICR mice (mean ± S.D, n=10)

<table>
<thead>
<tr>
<th>Group (mg/kg/d)</th>
<th>T Lymphocyte proliferation (%)</th>
<th>B Lymphocyte proliferation (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>5</td>
<td>19.2 ± 12.5**</td>
<td>16.2 ± 3.1**</td>
</tr>
<tr>
<td>20</td>
<td>27.6 ± 14.1**</td>
<td>21.9 ± 5.8**</td>
</tr>
<tr>
<td>80</td>
<td>10.3 ± 7.6*</td>
<td>14.1 ± 9.8**</td>
</tr>
</tbody>
</table>

* p< 0.05, ** p< 0.001 compared with control group.

To investigate the effect of LIG on the development of non-specific cytotoxic cells, the cytotoxic activity of NK cells was determined by LDH release assay using YAC-1 as target cells. The effect of LIG on the development of NK cell-mediated cytotoxicity was significantly different from the control at all three doses (p < 0.001), as Figure 1B shows.

Antitumor activity of LIG in H22-bearing mice

As shown in Figure 2, LIG significantly inhibited the growth of mouse transplanted H22 hepatoma. After 15 days treatment, the tumor inhibitory rate was 17.1, 46.9 and 27.7 % for LIG dose levels of 5, 20 and 80 mg/kg, respectively. LIG (20 mg/kg) exerted the highest inhibitory effect (46.9 %), close to that of DPP (52.6 %), which was the positive control.

DISCUSSION

The relationship between the occurrence, growth and decline of tumor and immune states is a major problem in tumor immunology. The discovery and identification of new antitumor drugs to potentiate immune function has become an important goal of research in immunopharmacology and oncotherapy. This study demonstrates the favorable immunomodulatory activity and antitumor effect of LIG, a phthalide derivative from Angelica sinensis.

Protective immunity against tumor comprises of non-specific, humoral and cellular immunity. Enhancement of phagocyte function is applicable to therapy of cancer because phagocytes act as regulator and effector cells in the immune system and phagocytosis represents an indispensable step in the immunological defense system [20]. Humoral defence via antibody response is mediated by B cells and other immune cells involved in antigen processing and immunization. Antigen–antibody complex can counteract toxins and defend the infection induced by the pathogen. Cell-mediated immune defense is mediated specifically by T cells including cytotoxic T cells. T cells can kill tumors and produce many lymphocyte factors consisting of macrophage mobile factor, lymphotoxin, transfer factor and interferon, which can enhance macrophage phagocytosis and the capacity of killing target cells [21]. NK cells mediate the immediate
Long et al.

killing of tumor cells and play a primary role in regulating immune responses as well [22].

In this study, we found that LIG significantly increased macrophage phagocytosis, hemolysin concentration, spleen lymphocyte proliferation, as well as CTL and NK cell activities in normal ICR mice, which suggests that LIG could enhance non-specific, humoral and cell-mediated immunity in normal mice. Based on this, it seems likely that LIG might have potential tumor therapeutic activity by enhancing the immune system.

On examining the effect of LIG on the H22-bearing ICR mice, it was found that LIG significantly inhibited the growth of mouse transplantable H22 hepatoma after treatment with LIG and the inhibitory effect of LIG (20 mg/kg) was close to that of the positive control, DPP (2 mg/kg).

The inhibitory effect of LIG on tumor growth as well as its immunomodulatory activity were dose-dependent, with the effect of the highest LIG (80 mg/kg) lower than that of the least dose (5mg/kg). Thus, 20mg/kg can be considered the optimum LIG dose to enhance host immune function and inhibit tumor growth in mice. It was reported that the key to regulating the immune function rests in the level of immune state in the body, not the level of dose. The immune level can be regulated in autoimmunity process and no effect was evident at higher doses above the limit. It was achieved by integral harmony function in which network of immune-neuroendocrine interactions was the priority [23].

CONCLUSION

The present study, to the best of our knowledge, reports for the first time the immunomodulatory and antitumor activities of LIG. The findings indicate that the antitumor activity of LIG is due to the augmentation of immune responses against tumors. Thus, the compound is a potentially attractive drug candidate for cancer therapy, possibly by combining it with chemotherapeutic agents with a view to achieving synergistically therapeutic outcome against tumors.

ACKNOWLEDGEMENT

The study was supported by Research Grants of National Key Laboratory of Chinese Medicine and Molecular Pharmacology in Shenzhen, China, and Hong Kong Polytechnic University Research Grants (A-256, G-YE98, G-YX14, G-YD78, G-T616, and G-T856).

REFERENCES

9. Huang LF, Li BY, Liang YZ, Guo FQ, Wang YL. Application of combined approach to analyze the